Director/PDMR Share Purchases

C4X Discovery Holdings PLC
09 April 2024
 

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

 

Director/PDMR Share Purchases

9 April 2024 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, was informed on 8 April 2024 that Clive Dix, Executive Chairman of the Company, purchased 485,320 ordinary shares of 0.01 pence each ("Ordinary Shares") in the Company at a price of 10.3 pence per share.

Following this purchase of shares, Clive Dix has a beneficial interest in 2,071,809 Ordinary Shares, representing approximately 0.82 per cent. of the Company's issued share capital.

Further information on the purchases is contained in the disclosure tables below.

 

Contacts

C4X Discovery Holdings


Mo Noonan, Communications

+44 (0)787 6444977



Panmure Gordon (UK) Limited (NOMAD and Broker)


Freddy Crossley, Emma Earl (Corporate Finance)

+44 (0)20 7886 2500

Rupert Dearden (Corporate Broking)




C4X Discovery Media - Consilium Strategic Communications


Mary-Jane Elliott, Chris Gardner

+44 (0)203 709 5700

 

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Clive Dix

2

Reason for the notification

a)

Position/status

Executive Chairman

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

C4X Discovery Holdings plc

b)

LEI

213800UHNL82E323O870

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of £0.01 each

 

 

GB00BQQ2RV18

b)

Nature of the transaction

Purchase of Shares

c)

Price(s) and volume(s)

  Price(s)

Volume(s)

10.3 pence

485,320

 

d)

Aggregated information

- Aggregated volume

- Price



n/a

e)

Date of the transaction

8 April 2024

f)

Place of the transaction

London Stock Exchange

 

 

Notes to Editors:

About C4X Discovery

C4X Discovery (C4XD) is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge technologies to efficiently deliver world‑leading medicines. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced molecular design and patient stratification capabilities, generating small molecule drug candidates across multiple disease indications focused on immuno-inflammation. We are advancing our internal portfolio which ranges from early-stage target opportunities to late-stage Drug Discovery programmes and we have two commercially partnered programmes with Sanofi and AstraZeneca, and one clinical stage candidate which has been acquired by Indivior.

 

For more information visit us at www.c4xdiscovery.com or follow us on twitter @C4XDiscovery.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings